Source-grounded facts extracted from iBio, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Martin Brenner was appointed as Office of the Chief Executive Officer (joint) at iBio, Inc..
“the Board approved the creation of the office of the Chief Executive Officer, whereby Mr. Robert Lutz, the Company's Chief Financial and Business Officer and Dr. Martin Brenner, the Company's Chief Scientific Officer will fill such role.”
Robert Lutz was appointed as Office of the Chief Executive Officer (joint) at iBio, Inc..
“the Board approved the creation of the office of the Chief Executive Officer, whereby Mr. Robert Lutz, the Company's Chief Financial and Business Officer and Dr. Martin Brenner, the Company's Chief Scientific Officer will fill such role.”
Thomas F. Isett resigned as Chief Executive Officer at iBio, Inc..
“Mr. Isett resigned as CEO of the Company effective December 1, 2022”
iBio, Inc. announced a restructuring with charges of approximately $1.7 million affecting Company-wide (workforce reduction primarily located at cGMP facility in Bryan, Texas) (approximately 60% of the current Company staffing levels).
“2023, although there is no assurance as to when, or for how much, the Company may be able to sell its CDMO assets. The Company expects to incur pre-tax charges of approximately $1.7 million for the employee reduction, most of which is expected to be incurred in the second and third quarter of fiscal year 2023. These charges will be substantially settled in cash and”
Chip Clark was appointed as Chairman of the Board at iBio, Inc..
“On November 1, 2022, Mr. Chip Clark was appointed as the Company’s Chairman of the Board.”
Randy J. Maddux resigned as Chief Operating Officer at iBio, Inc..
“On April 28, 2022, the Company received the resignation of Randy J. Maddux, its Chief Operating Officer, effective May 2, 2022.”
Seymour Flug resigned as director at iBio, Inc..
“On August 26, 2021, Seymour Flug resigned as a director of iBio, Inc. (the “Company”).”
William D. Clark was elected as Class III Director at iBio, Inc..
“On August 23, 2021, the Board of Directors (the “Board”) of iBio, Inc. (the “Company”) elected William D. (Chip) Clark as a Class III Director of the Board.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.